This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Vandepoele K, Van der Meulen J, Denys B. The NF1 hotspot in acute myeloid leukemia: what’s in a name? Leukemia. 2018;32:2715.
Eisfeld A-K, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, et al. NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia. 2018;32:2536–45.
den Dunnen JT. Sequence variant descriptions: HGVS nomenclature and Mutalyzer. Curr Protoc Hum Genet. 2016;90:7.13.1–19.
Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang Y-D, Mazor T, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47:1326–33.
Gröschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. Blood. 2015;125:133–9.
MacArthur JAL, Morales J, Tully RE, Astashyn A, Gil L, Bruford EA, et al. Locus Reference Genomic: reference sequences for the reporting of clinically relevant sequence variants. Nucleic Acids Res. 2014;42:D873–8. Database issue
Yen JL, Garcia S, Montana A, Harris J, Chervitz S, Morra M, et al. A variant by any name: quantifying annotation discordance across tools and clinical databases. Genome Med. 2017;9:7.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Eisfeld, AK., Blachly, J.S., Mrózek, K. et al. Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?. Leukemia 33, 809–810 (2019). https://doi.org/10.1038/s41375-018-0372-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0372-x